NASDAQ: CEROCero Therapeutics Holdings Inc Stock
$5.52-0.15 (-2.65%)
Updated Sep 17, 2025
CERO Price
$5.52
Fair Value Price
$1.45
Market Cap
$6.65M
52 Week Low
$4.27
52 Week High
$895.40
P/E
-0.08x
P/B
-4.07x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$14.08M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-4.8
Operating Cash Flow
-$13M
Beta
0.21
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CERO Overview
Phoenix Biotech Acquisition Corp. is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the healthcare and healthcare-related sectors in the U.S. and Europe. Phoenix Biotech Acquisition was incorporated in 2021 and is headquartered in Oakland, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CERO's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CERO
Ranked#464 of 479
Ranked#464 of 479
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.05 | A | |
| $7.70 | A | |
| $34.22 | A |
Be the first to know about important CERO news, forecast changes, insider trades & much more!
CERO News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CERO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CERO ($5.52) is overvalued by 280.68% relative to our estimate of its Fair Value price of $1.45 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CERO ($5.52) is not significantly undervalued (280.68%) relative to our estimate of its Fair Value price of $1.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CERO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CERO due diligence checks available for Premium users.
Valuation
CERO fair value
Fair Value of CERO stock based on Discounted Cash Flow (DCF)
Price
$5.52
Fair Value
$1.45
Overvalued by
280.68%
CERO ($5.52) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CERO ($5.52) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CERO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CERO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.08x
Industry
-97.28x
Market
37.36x
CERO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.07x
Industry
4.69x
CERO's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.4M
Profit Margin
0%
CERO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$6.2M
Liabilities
$7.8M
Debt to equity
-4.8
CERO's short-term liabilities ($7.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CERO's short-term assets ($4.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CERO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CERO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
$0.0
Financing
$2.7M
CERO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CERO vs Biotech Stocks
Cero Therapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.